🏥 Three Pillars of Clinical Mass Spectrometry Translation
Translational OncologyPillar 1 • WHO CNS5 Glioma Mapping
Integrated Oncometabolite & Phospho-Profiling
Integrating proteomic phosphorylation signatures and metabolomic D-2-hydroxyglutarate (D-2HG) accumulation to classify Astrocytoma IDH-mutant, Oligodendroglioma 1p/19q-codeleted, and Glioblastoma IDH-wildtype.
Pillar 2 • Targeted Assay Design
Skyline MRM & PRM Multiplex Verification
Transitioning from untargeted discovery into targeted clinical assays: transition selection, heavy isotope-labeled internal standards (AQUA), collision energy optimization, and lower limit of quantification (LLOQ) validation.
Pillar 3 • Regulatory Translation
LDT vs. IVD & Molecular Tumor Board
Overcoming pre-analytical cold ischemia drift, achieving CLIA/CAP analytical validity (precision, linearity, recovery), and synthesizing multi-omics findings into actionable molecular tumor board recommendations.
👥
Who Should Attend
🩺
Translational Researchers & Oncologists
Bridging genomic mutations with functional proteomic and metabolomic phenotypes in patient tissues.
🧪
Mass Spectrometry & Analytical Chemists
Moving from standard raw spectrum files into reproducible machine learning classification panels.
🔬
Clinical Laboratory Scientists & Pathologists
Designing targeted MRM/PRM assays and navigating FDA/CLIA regulatory validation (LDT vs. IVD).
🎓
Proteomics PhD Scholars & Postdocs
Mastering DDA/DIA spectra searching, LFQ quantification, XCMS 3 alignment, and Skyline targeted design.
🎯
Learning Outcomes
- Execute Data-Dependent (DDA) and Data-Independent (DIA) Orbitrap mass spectrometry discovery workflows.
- Compute peptide-spectrum match FDR control and Label-Free Quantification (LFQ) via MSFragger & Philosopher.
- Align untargeted metabolomics chromatograms, pick peaks, and annotate adducts with XCMS 3.
- Mitigate cold ischemia and batch drift using ComBat and defensive missing-value imputation.
- Engineer supervised machine learning biomarker panels using PLS-DA and Random Forests with cross-validation.
- Build targeted MRM/PRM verification assays in Skyline and translate findings into WHO CNS5 molecular glioma subtyping.
🔬 4-PHASE CURRICULUM ARCHITECTURE
Clinical Mass Spectrometry Roadmap & Benchmarks
Self-paced, hands-on masterclass curriculum structured into 4 foundational phases with production command-line recipes and clinical WHO CNS5 glioma mass spec datasets.
PHASE 1
Biology & Instrumentation
Modules 01–03 • Orbitrap DDA/DIA & Glioma Cohorts
- Functional proteome, Warburg rewiring & oncometabolites
- High-resolution Orbitrap & Q-TOF instrument principles
- Data-Dependent (DDA) vs Data-Independent (DIA) acquisition
- Cold ischemia & pre-analytical biospecimen variables
- 2021 WHO CNS5 glioma molecular subtyping framework
PHASE 2
Biomarker Discovery
Modules 04–06 • MSFragger LFQ, XCMS 3 & Batch Effects
- MSFragger ultrafast database search & decoy FDR
- Label-Free Quantification (LFQ) via Philosopher
- Untargeted metabolomics peak detection in XCMS 3
- Retention time alignment & adduct deconvolution
- ComBat batch adjustment & missing value imputation
PHASE 3
Machine Learning & MRM/PRM
Modules 07–09 • PLS-DA, Random Forests & Skyline
- Candidate biomarker prioritization attrition funnel
- Supervised PLS-DA with VIP score thresholding
- Boruta Random Forest panels with nested CV
- Targeted mass spec assay design in Skyline 23+
- Transition selection & collision energy optimization
PHASE 4
Validation & MTB Translation
Modules 10–12 • LOD/LOQ, LDT vs IVD & Multi-Omics
- Analytical LOD, LOQ, precision & linearity metrics
- Diagnostic sensitivity, specificity, PPV & NPV
- FDA/CLIA regulatory pathways: LDT vs IVD
- Reimbursement barriers and companion diagnostics
- Multi-omics brain tumor case studies for Tumor Boards
COURSE CURRICULUM
12 Comprehensive Modular Chapters
All modules include Orbitrap spectral recipes, R / Python scripts, and benchmark glioma datasets
Peer-Reviewed Foundations
Primary high-resolution mass spec, XCMS 3 & WHO CNS5 oncology citations for Track 17
📚 Foundational Literature & Methodology Benchmarks
🔬 Mass Spectrometry, MSFragger & Untargeted Metabolomics
- Kong AT, Leprevost FV, Avtonomov DM, et al. (2017). MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics. Nature Methods 14(5):513–520. doi:10.1038/nmeth.4256
- Smith CA, Want EJ, O'Maille G, et al. (2006). XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Analytical Chemistry 78(3):779–787. doi:10.1021/ac051437y
- Aebersold R, Mann M. (2016). Mass-spectrometric exploration of proteome structure and function. Nature 537:347–355. doi:10.1038/nature19949
- Cox J, Mann M. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature Biotechnology 26:1367–1372. doi:10.1038/nbt.1511
🏥 Clinical Oncology, Targeted Assays & Precision Diagnostics
- MacLean B, Tomazela DM, Shulman N, et al. (2010). Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26(7):966–968. doi:10.1093/bioinformatics/btq054
- Louis DN, Perry A, Wesseling P, et al. (2021). The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology 23(8):1231–1251. doi:10.1093/neuonc/noab106
- Dang L, White DW, Gross S, et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744. doi:10.1038/nature08617
- Leek JT, Johnson WE, Parker HS, et al. (2012). The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28(6):882–883. doi:10.1093/bioinformatics/bts034
Looking for Other Bioinformatics Specializations?
Explore all 20 Flagship Curricula across Precision Oncology, Mass Spectrometry, Genomics, and Nextflow Cloud Pipelines.